anti- ALPL antibody

Este producto es parte de ALPL - Alkaline phosphatase tissue-nonspecific isozyme
anti- ALPL antibody

Pida mas información

935106861

info@markelab.com

Precio

Precio a consultar

Antibody anti-ALPL

proveedor

FineTest

reference

FNab00347

Tested Applications

ELISA, WB, IHC, FC

reactivity

human

status

RUO

clonality

polyclonal

Descripción

There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney(tissue non-specific). The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. ALPL(Alkaline phosphatase, tissue-nonspecific isozyme) is also named as AP-TNAP, TNSALP and belongs to the alkaline phosphatase family. It can exsit as a homodimer with the molecular weight of 140 kDa(PMID:18724009). ALPL was synthesized as a 66-kDa endo-b-N-acetylglucos-aminidase H(Endo H)-sensitive form, and processed to an 80-kDa mature form, which is anchored to the plasma membrane via glycosylphosphatidylinositol(GPI)(PMID:10839996).This antibody can bind the four mentioned alkaline phosphatases.


Background

Alkaline phosphatase, tissue-nonspecific isozyme (ALPL) is an enzyme encoded by the ALPL gene in humans. It is also commonly known as tissue-nonspecific alkaline phosphatase (TNAP). ALPL is a type of alkaline phosphatase found in bone, liver, kidney, and intestine. ALPL plays a crucial role in bone mineralization and is involved in the regulation of phosphate metabolism. It catalyzes the hydrolysis of phosphate esters in an alkaline environment, leading to the release of inorganic phosphate. In bone tissue, ALPL is primarily expressed by osteoblasts, where it helps in the mineralization process by generating inorganic phosphate ions, which are essential for the formation of hydroxyapatite crystals, the main component of bone mineral. Deficiencies or mutations in the ALPL gene can lead to a rare genetic disorder known as hypophosphatasia (HPP). HPP is characterized by defective bone mineralization, resulting in weak and soft bones, skeletal abnormalities, and a range of other symptoms depending on the severity of the condition.

Características del producto

category

Primary Antibodies


clonality

polyclonal


reactivity

human


immunogen target

alkaline phosphatase, liver/bone/kidney


host

Rabbit


isotype

IgG


conjugation

Unconjugated


form

liquid


tested applications

ELISA, WB, IHC, FC


observerd MW

60-80 kDa


purity

≥95% as determined by SDS-PAGE


purification

Immunogen affinity purified


recommended dilution

WB: 1:500-1:3000; IHC: 1:20-1:200


size 1

100µg


storage

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)


or code

ALPL


alias

AP-TNAP,TNS-ALP


note

This product is for research use only.


Quizá le pueda interesar

anti- ALPL antibody

anti- ALPL antibody

proveedor

FineTest

reference

FNab00347

Tested Applications

ELISA, WB, IHC, FC

reactivity

human

status

RUO

clonality

polyclonal

There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bon...

Precio a consultar

Ver más

anti- ALPL antibody

anti- ALPL antibody

proveedor

FineTest

reference

FNab10377

Tested Applications

ELISA, WB, IHC

reactivity

human

status

RUO

clonality

polyclonal

There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bon...

Precio a consultar

Ver más

Recombinant Human ALPL

Recombinant Human ALPL

proveedor

FineTest

reference

P0476

Tested Applications

Western Blot, ELISA

status

RUO

Precio a consultar

Ver más